Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme trial: TPEx versus EXTREME as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Fiche publication

Date publication

août 2025

Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel

Tous les auteurs :
Fraslin AM, Aupérin A, Even C, Fayette J, Saada-Bouzid E, Lafond C, Geoffrois L, ,Bourhis J, Guigay J, Bonastre J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40848743

Résumé

The randomized GORTEC 2014-01 TPExtreme trial showed no significant improvement in overall survival with TPEx chemotherapy regimen (docetaxel-platinum-cetuximab) versus EXTREME regimen (platinum-fluorouracil-cetuximab) in first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the TPEx regimen had a favorable safety profile, and could provide an alternative to standard of care with the EXTREME regimen in this setting. Our aim was to assess the cost-utility of the TPEx strategy versus EXTREME strategy in the French setting.